Background: Chemerin is a newly discovered adipokine that regulates adipocyte development, metabolic function as well as immune function. Anti-Müllerian hormone (AMH) is a dimeric glycoprotein that belongs to the transforming growth factor-beta family.
Aim of the study: was to evaluate the serum levels of Chemerin and AMH in one trial to show their possible involvement in the pathogenesis of PCOS and their association with obesity.
Subjects and methods: This study was performed on eighty subjects divided into 4 groups: Group I: 20 non-obese control (BMI< 30), Group II: 20 non-obese patient with polycystic ovarian syndrome (BMI< 30), Group III: 20 obese Control (BMI ≥ 30) and Group IV: 20 obese patient with PCOS (BMI ≥ 30). Serum levels of Chemerin and AMH were estimated by ELISA.
Results: Results showed a significant increase in serum levels of Chemerin and AMH in (non-obese and obese) PCOS groups when compared to their controls. Results showed also a significant increase in the serum level of Chemerin in obese PCOS group when compared to non-obese PCOS group. While a significant decrease in serum level of AMH in obese PCOS group when compared to non-obese PCOS group. There were a significant positive correlation between Chemerin and AMH in PCOS groups.
Conclusion: Chemerin together with AMH may be used as a biomarker for early detection of PCO and Clinical parameters as Infertility and Hyper and rogenism in women with PCOS.